FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Int J Hematol / Efficacy of combination therapy with anti-thymocyte globulin...
International journal of hematology2016; 104(4); 446-453; doi: 10.1007/s12185-016-2046-7

Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations.

Abstract: Anti-thymocyte globulin (ATG) is a key drug in immunosuppressive therapy for patients with aplastic anemia. The mainstay of ATG therapy had been a horse ATG (hATG) formulation, Lymphoglobulin or ATGAM, but Lymphoglobulin was recently discontinued, and Thymoglobulin, a rabbit ATG (rATG) formulation, is currently used as the first-line drug in many countries, including Japan. However, a recent randomized clinical trial reported significantly unfavorable outcomes associated with the use of rATG regimens. We retrospectively analyzed clinical outcomes of adult patients with moderate to severe aplastic anemia who were treated with 3.5 mg/kg of Thymoglobulin (n = 22) or 15 mg/kg of Lymphoglobulin (n = 25) in our facility. The estimated overall response rates in the rATG and hATG groups were 64.6 versus 56.0 % at 6 months, and 76.4 versus 69.2 % at 12 months, respectively; and there was no statistical difference between the two groups (P = 0.32). Overall survival at 24 months was not significantly different: rATG 89.8 % versus hATG 96.0 % (P = 0.39). Early phase infection was observed in 37.5 % of cases in the rATG and 14.8 % in the hATG group, but the frequency was not statistically different (P = 0.107). Our data indicate that Thymoglobulin at a dose of 3.5 mg/kg is a viable alternative when hATG is not available.
Get Full Text
Publication Date: 2016-06-23 PubMed ID: 27338268DOI: 10.1007/s12185-016-2046-7Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The research paper explores the use of anti-thymocyte globulin (ATG) in treating aplastic anemia in adults. It compares the efficacy of rabbit and horse formulations of ATG, with the conclusion that rabbit ATG, specifically Thymoglobulin, is a viable alternative when horse ATG, known as Lymphoglobulin, is not available.

Background

  • This research was prompted by the discontinuation of Lymphoglobulin, the horse ATG (hATG) formulation, which was primarily used for immunosuppressive therapy in patients with aplastic anemia.
  • Despite the common use of Thymoglobulin, a rabbit ATG (rATG) formulation in many countries, a past clinical trial found unfavorable results linked with the rATG regime.

Methods and Outcome Measure

  • The researchers conducted a retrospective study, analyzing the clinical outcomes of adult patients with moderate to severe aplastic anemia who were administered either Thymoglobulin or Lymphoglobulin at specific doses.
  • The response rates show that the rATG group had better response rates at 6 and 12 months, but there was no major statistical difference in comparison to the hATG group.
  • Additionally, the survival rate at 24 months showed no significant statistical difference.
  • An early phase infection was noted to be higher in patients who received rATG than hATG, although the frequency has no statistical significance.

Conclusion

  • In conclusion, the study found that Thymoglobulin at a dose of 3.5 mg/kg could be an effective alternative when Lymphoglobulin (hATG) is unavailable.
  • While the results show a slight improvement in terms of response rates with rATG, the differences were not statistically significant, suggesting that both treatments may be effective in treating aplastic anemia in adults.

Cite This Article

APA
Suzuki T, Kobayashi H, Kawasaki Y, Okazuka K, Hatano K, Fujiwara S, Oh I, Ohmine K, Kanda Y. (2016). Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol, 104(4), 446-453. https://doi.org/10.1007/s12185-016-2046-7

Publication

International journal of hematology
ISSN: 1865-3774
NlmUniqueID: 9111627
Country: Japan
Language: English
Volume: 104
Issue: 4
Pages: 446-453

Researcher Affiliations

Suzuki, Takahiro
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Kobayashi, Hiroyuki
  • Nasu Red Cross Hospital, Otawara, Tochigi, Japan.
Kawasaki, Yasufumi
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Okazuka, Kiyoshi
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Hatano, Kaoru
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Fujiwara, Shin-Ichiro
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Oh, Iekuni
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Ohmine, Ken
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan.
Kanda, Yoshinobu
  • Division of Hematology, Department of Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi, 329-0498, Japan. ycanda-tky@umin.ac.jp.

MeSH Terms

  • Adult
  • Anemia, Aplastic / drug therapy
  • Animals
  • Antilymphocyte Serum / administration & dosage
  • Cyclosporine / administration & dosage
  • Drug Therapy, Combination / methods
  • Drug Therapy, Combination / mortality
  • Drug Therapy, Combination / standards
  • Horses
  • Humans
  • Immunoglobulins / administration & dosage
  • Immunosuppressive Agents / therapeutic use
  • Rabbits
  • Treatment Outcome

References

This article includes 25 references
  1. Atta EH, Dias DS, Marra VL, de Azevedo AM. Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study.. Ann Hematol 2010 Sep;89(9):851-9.
    pubmed: 20373101doi: 10.1007/s00277-010-0944-ygoogle scholar: lookup
  2. Kojima S, Nakao S, Young N, Bacigalupo A, Gerard G, Hirano N, Maciejewski J, Deeg J, Marsh J, Zhang FK, Lee JW, Ozawa K. The Third Consensus Conference on the treatment of aplastic anemia.. Int J Hematol 2011 Jun;93(6):832-837.
    pubmed: 21617886doi: 10.1007/s12185-011-0873-0google scholar: lookup
  3. Feng X, Kajigaya S, Solomou EE, Keyvanfar K, Xu X, Raghavachari N, Munson PJ, Herndon TM, Chen J, Young NS. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro.. Blood 2008 Apr 1;111(7):3675-83.
    pubmed: 18250226doi: 10.1182/blood-2008-01-130146google scholar: lookup
  4. Zheng Y, Liu Y, Chu Y. Immunosuppressive therapy for acquired severe aplastic anemia (SAA): a prospective comparison of four different regimens.. Exp Hematol 2006 Jul;34(7):826-31.
    pubmed: 16797409doi: 10.1016/j.exphem.2006.03.017google scholar: lookup
  5. Frickhofen N, Heimpel H, Kaltwasser JP, Schrezenmeier H. Antithymocyte globulin with or without cyclosporin A: 11-year follow-up of a randomized trial comparing treatments of aplastic anemia.. Blood 2003 Feb 15;101(4):1236-42.
    pubmed: 12393680doi: 10.1182/blood-2002-04-1134google scholar: lookup
  6. Shao YQ, Li XX, Ge ML, Shi J, Zhang J, Huang JB, Huang ZD, Nie N, Zheng YZ. [A long-term follow up study on 345 severe aplastic anemia patients treated with antithymocyte globulin/lymphoglobulin].. Zhonghua Xue Ye Xue Za Zhi 2013 Jan;34(1):30-5.
    pubmed: 23597461
  7. Afable MG 2nd, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, Sekeres MA, Lichtin A, Advani A, Kalaycio M, Tiu RV, O'Keefe CL, Maciejewski JP. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia.. Haematologica 2011 Sep;96(9):1269-75.
    pubmed: 21606164doi: 10.3324/haematol.2011.042622google scholar: lookup
  8. Vallejo C, Montesinos P, Polo M, Cuevas B, Morado M, Rosell A, Xicoy B, Díez JL, Salamero O, Cedillo Á, Martínez P, Rayón C. Rabbit antithymocyte globulin versus horse antithymocyte globulin for treatment of acquired aplastic anemia: a retrospective analysis.. Ann Hematol 2015 Jun;94(6):947-54.
    pubmed: 25672649doi: 10.1007/s00277-015-2305-3google scholar: lookup
  9. Shin SH, Yoon JH, Yahng SA, Lee SE, Cho BS, Eom KS, Kim YJ, Lee S, Min CK, Kim HJ, Cho SG, Kim DW, Min WS, Park CW, Lee JW. The efficacy of rabbit antithymocyte globulin with cyclosporine in comparison to horse antithymocyte globulin as a first-line treatment in adult patients with severe aplastic anemia: a single-center retrospective study.. Ann Hematol 2013 Jun;92(6):817-24.
    pubmed: 23318980doi: 10.1007/s00277-013-1674-8google scholar: lookup
  10. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond.. Leukemia 2007 Jul;21(7):1387-94.
    pubmed: 17410187doi: 10.1038/sj.leu.2404683google scholar: lookup
  11. Tichelli A, Schrezenmeier H, Socié G, Marsh J, Bacigalupo A, Dührsen U, Franzke A, Hallek M, Thiel E, Wilhelm M, Höchsmann B, Barrois A, Champion K, Passweg JR. A randomized controlled study in patients with newly diagnosed severe aplastic anemia receiving antithymocyte globulin (ATG), cyclosporine, with or without G-CSF: a study of the SAA Working Party of the European Group for Blood and Marrow Transplantation.. Blood 2011 Apr 28;117(17):4434-41.
    pubmed: 21233311doi: 10.1182/blood-2010-08-304071google scholar: lookup
  12. Young NS, Calado RT, Scheinberg P. Current concepts in the pathophysiology and treatment of aplastic anemia.. Blood 2006 Oct 15;108(8):2509-19.
    pubmed: 16778145doi: 10.1182/blood-2006-03-010777google scholar: lookup
  13. Locasciulli A, Oneto R, Bacigalupo A, Socié G, Korthof E, Bekassy A, Schrezenmeier H, Passweg J, Führer M. Outcome of patients with acquired aplastic anemia given first line bone marrow transplantation or immunosuppressive treatment in the last decade: a report from the European Group for Blood and Marrow Transplantation (EBMT).. Haematologica 2007 Jan;92(1):11-8.
    pubmed: 17229630doi: 10.3324/haematol.10075google scholar: lookup
  14. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome.. Br J Haematol 2012 May;157(3):312-20.
    pubmed: 22360602doi: 10.1111/j.1365-2141.2012.09064.xgoogle scholar: lookup
  15. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical statistics.. Bone Marrow Transplant 2013 Mar;48(3):452-8.
    pubmed: 23208313doi: 10.1038/bmt.2012.244google scholar: lookup
  16. Chang MH, Kim KH, Kim HS, Jun HJ, Kim DH, Jang JH, Kim K, Jung CW. Predictors of response to immunosuppressive therapy with antithymocyte globulin and cyclosporine and prognostic factors for survival in patients with severe aplastic anemia.. Eur J Haematol 2010 Feb 1;84(2):154-9.
    pubmed: 19912311doi: 10.1111/j.1600-0609.2009.01378.xgoogle scholar: lookup
  17. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia.. N Engl J Med 2011 Aug 4;365(5):430-8.
    pubmed: 21812672doi: 10.1056/NEJMoa1103975google scholar: lookup
  18. Sakamoto T, Obara N, Kurita N, Sakata-Yanagimoto M, Nishikii H, Yokoyama Y, Suzukawa K, Hasegawa Y, Chiba S. Effectiveness and safety of rabbit anti-thymocyte globulin in Japanese patients with aplastic anemia.. Int J Hematol 2013 Sep;98(3):319-22.
    pubmed: 23963878doi: 10.1007/s12185-013-1418-5google scholar: lookup
  19. Scheinberg P, Fischer SH, Li L, Nunez O, Wu CO, Sloand EM, Cohen JI, Young NS, John Barrett A. Distinct EBV and CMV reactivation patterns following antibody-based immunosuppressive regimens in patients with severe aplastic anemia.. Blood 2007 Apr 15;109(8):3219-24.
    pubmed: 17148582doi: 10.1182/blood-2006-09-045625google scholar: lookup
  20. Yoshimi A, Niemeyer CM, Führer MM, Strahm B. Comparison of the efficacy of rabbit and horse antithymocyte globulin for the treatment of severe aplastic anemia in children.. Blood 2013 Jan 31;121(5):860-1.
    pubmed: 23372153doi: 10.1182/blood-2012-10-461509google scholar: lookup
  21. Takahashi Y, Muramatsu H, Sakata N, Hyakuna N, Hamamoto K, Kobayashi R, Ito E, Yagasaki H, Ohara A, Kikuchi A, Morimoto A, Yabe H, Kudo K, Watanabe K, Ohga S, Kojima S. Rabbit antithymocyte globulin and cyclosporine as first-line therapy for children with acquired aplastic anemia.. Blood 2013 Jan 31;121(5):862-3.
    pubmed: 23372154doi: 10.1182/blood-2012-11-465633google scholar: lookup
  22. Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G. Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.. Blood 2012 Jun 7;119(23):5391-6.
    pubmed: 22544699doi: 10.1182/blood-2012-02-407684google scholar: lookup
  23. Li X, Shi J, Ge M, Shao Y, Huang J, Huang Z, Zhang J, Nie N, Zheng Y. Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience.. PLoS One 2013;8(3):e56648.
    pubmed: 23554855doi: 10.1371/journal.pone.0056648google scholar: lookup
  24. Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, Muramatsu H, Ohara A, Kosaka Y, Yang W, Kim HK, Zhu X, Kojima S. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children.. Haematologica 2014 Apr;99(4):664-71.
    pubmed: 24213150doi: 10.3324/haematol.2013.089268google scholar: lookup
  25. Davies JK, Guinan EC. An update on the management of severe idiopathic aplastic anaemia in children.. Br J Haematol 2007 Feb;136(4):549-64.
    pubmed: 17214739doi: 10.1111/j.1365-2141.2006.06461.xgoogle scholar: lookup

Citations

This article has been cited 9 times.
  1. Yang W, Liu X, Zhao X, Zhang L, Peng G, Ye L, Zhou K, Li Y, Li J, Fan H, Yang Y, Xiong Y, Jing L, Zhang F. Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study.. Ther Adv Hematol 2023;14:20406207221146031.
    doi: 10.1177/20406207221146031pubmed: 36654738google scholar: lookup
  2. Kanda Y, Mori T, Narita A, Wolter KD, Yoshimatsu H, Nishimura K. Efficacy and safety of equine anti-thymocyte immunoglobulin (eATG) in three Japanese patients with moderate to very severe aplastic anemia: a case series.. Int J Hematol 2023 Jan;117(1):37-43.
    doi: 10.1007/s12185-022-03496-5pubmed: 36441357google scholar: lookup
  3. Hu J, Zhang L, Zhao X, Liu X, Jing L, Zhou K, Li Y, Li Y, Li J, Ye L, Peng G, Fan H, Yang W, Yang Y, Xiong Y, Song L, Zhang F. First-line immunosuppressive therapy with rATG and CsA for severe aplastic anemia: 15 years' experience.. Ann Hematol 2022 Nov;101(11):2405-2412.
    doi: 10.1007/s00277-022-04952-2pubmed: 36151352google scholar: lookup
  4. Imada K, Obara N, Iida H, Imajo K, Maeda T, Usuki K, Fanghong Z, Hombo Y, Tajima T, Kumagai A, Matsuda A, Nakao S. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan.. Intern Med 2021 Apr 15;60(8):1159-1168.
    doi: 10.2169/internalmedicine.6063-20pubmed: 33229810google scholar: lookup
  5. Jiang J, Cai Y, Wan L, Yang J, Wang C. Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia.. Int J Hematol 2020 Mar;111(3):360-368.
    doi: 10.1007/s12185-019-02807-7pubmed: 31900878google scholar: lookup
  6. Sasaki N, Shimura K, Yoshida M, Uoshima N, Kiyota M, Hatsuse M, Uchiyama H, Chinen Y, Kobayashi T, Nakao M, Takahashi R, Nakano-Akamatsu S, Kaneko H, Kobayashi Y, Shimazaki C, Taniwaki M, Kuroda J. Immunosuppressive therapy with rabbit antithymocyte globulin therapy for acquired aplastic anemia: a multi-institutional retrospective study in Japanese adult patients.. Int J Hematol 2019 Mar;109(3):278-285.
    doi: 10.1007/s12185-018-02583-wpubmed: 30627868google scholar: lookup
  7. Ding SX, Fu R. [Progress in prediction and recovery of immunosuppressive therapy in patients with severe aplastic anemia].. Zhonghua Xue Ye Xue Za Zhi 2018 Nov 14;39(11):960-964.
    doi: 10.3760/cma.j.issn.0253-2727.2018.11.019pubmed: 30486598google scholar: lookup
  8. Imi T, Katagiri T, Hosomichi K, Zaimoku Y, Hoang Nguyen V, Nakagawa N, Tajima A, Yoshizato T, Ogawa S, Nakao S. Sustained clonal hematopoiesis by HLA-lacking hematopoietic stem cells without driver mutations in aplastic anemia.. Blood Adv 2018 May 8;2(9):1000-1012.
    doi: 10.1182/bloodadvances.2017013953pubmed: 29720492google scholar: lookup
  9. Bacigalupo A, Oneto R, Schrezenmeier H, Hochsmann B, Dufour C, Kojima S, Zhu X, Chen X, Issaragrisil S, Chuncharunee S, Jeong DC, Giammarco S, Van Lint MT, Zheng Y, Vallejo C. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: Outcome of 955 patients treated 2001-2012.. Am J Hematol 2018 May;93(5):643-648.
    doi: 10.1002/ajh.25081pubmed: 29498107google scholar: lookup
Subscribe to our newsletter
Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.